Follow
David Matheson
David Matheson
Verified email at wlv.ac.uk
Title
Cited by
Cited by
Year
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
20522016
Abiraterone for prostate cancer not previously treated with hormone therapy
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
17112017
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...
The Lancet 392 (10162), 2353-2366, 2018
10502018
Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ...
Annals of Oncology 30 (12), 1992-2003, 2019
3462019
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
MR Sydes, MR Spears, MD Mason, NW Clarke, DP Dearnaley, ...
Annals of Oncology 29 (5), 1235-1248, 2018
2692018
STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
Lancet 387 (10024), 1163-1177, 2016
2082016
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised …
G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ...
The lancet 399 (10323), 447-460, 2022
2072022
Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial
ND James, MR Spears, NW Clarke, DP Dearnaley, MD Mason, CC Parker, ...
JAMA oncology 2 (3), 348-357, 2016
2002016
Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer
AP Hoyle, A Ali, ND James, A Cook, CC Parker, JS De Bono, G Attard, ...
European urology 76 (6), 719-728, 2019
1772019
An introduction to the study of education
D Matheson
Routledge, 2014
140*2014
How well prepared are medical students for their first year as doctors? The views of consultants and specialist registrars in two teaching hospitals
C Matheson, D Matheson
Postgraduate Medical Journal 85 (1009), 582-589, 2009
1172009
Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed …
CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...
Lancet 392 (10162), 2353-2366, 2018
1162018
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial
G Attard, MR Sydes, MD Mason, NW Clarke, D Aebersold, JS de Bono, ...
European urology, 2014
782014
Lifelong learning and lifelong education: A critique
D Matheson, C Matheson
Research in Post‐Compulsory Education 1 (2), 219-236, 1996
701996
Adding celecoxib with or without zoledronic acid for hormone-naďve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized …
MD Mason, NW Clarke, ND James, DP Dearnaley, MR Spears, ...
Journal of clinical oncology 35 (14), 1530, 2017
642017
Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial
HL Rush, L Murphy, AK Morgans, NW Clarke, AD Cook, G Attard, ...
Journal of clinical oncology: official journal of the American Society of …, 2022
482022
Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment …
S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ...
European urology 83 (3), 267-293, 2023
472023
Languages of Scotland: Culture and the classroom
C Matheson, D Matheson
Comparative Education 36 (2), 211-221, 2000
462000
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
CC Parker, ND James, CD Brawley, NW Clarke, A Ali, CL Amos, G Attard, ...
PLoS medicine 19 (6), e1003998, 2022
392022
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
ND James, NW Clarke, A Cook, A Ali, AP Hoyle, G Attard, CD Brawley, ...
International Journal of Cancer 151 (3), 422-434, 2022
342022
The system can't perform the operation now. Try again later.
Articles 1–20